The Global Health Initiative is a multidisciplinary university-wide effort to reduce health inequalities among underserved populations locally and worldwide through education, research, service and development of partnerships.
Global Health in Education, Research and Service
The GHI is distinguished by an integrative, overarching approach to the fundamentally interrelated problems of health and development. One key advantage of the GHI is its ability to bring together the social, cultural, and human dimensions of global health problems and their biomedical and technological elements under a single umbrella. Building upon Brown's expertise in both population analysis and infectious disease intervention, the Initiative offers high impact education, research, and service opportunities for students and faculty, and addresses issues of capacity, infrastructure, environment, and health care delivery to reduce the burden of disease in impoverished communities.
Brown Faculty in the News
Marc Simpao, MD, and his wife Kayan Lewis, PhD, collaborated with faculty and post-graduate residents and the University of Rwanda on a grant that was accepted by the Swedish International Development Agency (Sida).
The grant will fund two major studies on Deep Vein Thrombosis (DVT) in Rwanda. One study will assess prevalence data on DVT in Rwanda, where there currently is no prevalence data on DVT, and the other will address various risk assessment models for predicting DVT/PE in Rwanda.
A team of researchers from Brown and the Lifespan Center for International Health Research (CIHR), led by Dr. Jonathan Kurtis, Director of CIHR and Professor of Pathology and Laboratory Medicine at Brown Medical School, published a paper in the May 23 edition of the journal Science on their research into a protein of key consequence for the course of malaria in children. Click here for the full article.
For more information:
Dr. Erna Milunka Kojic, MD, Associate Professor of Medicine at Brown, is the lead author of a new AIDS Clinical Trials Group (ACTG) study on the safety and immunogenicity of the human papilloma virus (HPV) vaccine in HIV infected women in Brazil, South Africa and the United States. This is the first study showing that the HPV vaccine is safe and can induce an immune response in this population. Published in the journal Clinical Infectious Diseases, the study found that most women could make antibodies to the various strains of HPV in the Gardasil vaccine even if they had HIV for years prior to the vaccination.
For more information, follow the links below: